Related Experiment Video
Updated: Aug 6, 2026

Treating Low Back Pain in Failed Back Surgery Patients with Multicolumn-lead Spinal Cord Stimulation
Published on: June 26, 2018
Intensive, interdisciplinary pain treatment in fibrous dysplasia/McCune-Albright syndrome
Camryn Berry1, Edin Randall2, Julie Shulman3
1Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, United States.
Abstract:
Pain in fibrous dysplasia/McCune-Albright syndrome (FD/MAS) remains inadequately treated. The pilot study was aimed to determine the feasibility (ie, completion, retention, and acceptability) and to explore the effectiveness of an intensive interdisciplinary pain treatment (IIPT) using a biopsychosocial approach in patients with FD/MAS. Five patients (4 females and 1 male; 22-30 yr old) with FD/MAS, with baseline pain severity of 4+ (0-10 scale) were enrolled. A 3-wk intervention (4 d/wk; 3-4 h/d) integrating psychological, physical, and occupational therapies was administered to patients. Study measures included patient-reported outcomes at treatment admission (week 0), discharge (week 3), and follow-up (week 15). Physician Global Assessments (PGA) at weeks 0 and 3 were also collected. All 5 patients completed the 3-wk intervention and follow-up assessment and reported a high degree of acceptability, appropriateness, and feasibility of the intervention. Average pain severity decreased after treatment, with mean changes of -3.0 and -3.2 points at weeks 3 and 15, respectively. Patients demonstrated improvements in pain interference, external pain expression (measured with the pain behavior scale), and pain catastrophizing. Trends of decreased anxiety and depression were observed. Overall health-related quality of life improved at treatment discharge, which was consistent with the PGA (ie, +2 to +3) scores. This pilot study demonstrates that IIPT was feasible and showed initial clinical benefit across multiple dimensions in a small cohort of patients with FD/MAS. Larger-scale, controlled trials are needed for further validation.